A systematic review of genome-wide association studies of antipsychotic response

Josiah D. Allen, Jeffrey R Bishop

Research output: Contribution to journalReview article

Abstract

Clinical symptom response to antipsychotic medications is highly variable. Genome-wide association studies (GWAS) provide a 'hypothesis-free' method of interrogating the genome for biomarkers of antipsychotic response. We performed a systematic review of GWAS findings for antipsychotic efficacy or effectiveness. 14 studies met our inclusion criteria, ten of which examined antipsychotic response using quantitative rating scales to measure symptom improvement. 15 genome-wide significant loci were identified, seven of which were replicated in other antipsychotic GWAS publications: CNTNAP5, GRID2, GRM7, 8q24 (KCNK9), PCDH7, SLC1A1 and TNIK. Notably, four replicated loci are involved in glutamatergic pathways. Additional validation and evaluation of the biological significance of these markers is warranted. These markers should also be evaluated for clinical utility, especially in the con of other validated pharmacogenomic variants (e.g., CYP450 genes). These findings may generate new avenues for development of novel antipsychotic treatments.

Original languageEnglish (US)
Pages (from-to)291-306
Number of pages16
JournalPharmacogenomics
Volume20
Issue number4
DOIs
StatePublished - Mar 2019

Fingerprint

Genome-Wide Association Study
Antipsychotic Agents
Biomarkers
Genome
Publications
Genes

Keywords

  • GWAS
  • antipsychotic
  • genome-wide association study
  • pharmacogenomics
  • psychopharmacology
  • schizophrenia
  • systematic review
  • treatment response

PubMed: MeSH publication types

  • Journal Article
  • Research Support, N.I.H., Extramural

Cite this

A systematic review of genome-wide association studies of antipsychotic response. / Allen, Josiah D.; Bishop, Jeffrey R.

In: Pharmacogenomics, Vol. 20, No. 4, 03.2019, p. 291-306.

Research output: Contribution to journalReview article

@article{ef02da56eb9445fcbbafdecfe6eec4ca,
title = "A systematic review of genome-wide association studies of antipsychotic response",
abstract = "Clinical symptom response to antipsychotic medications is highly variable. Genome-wide association studies (GWAS) provide a 'hypothesis-free' method of interrogating the genome for biomarkers of antipsychotic response. We performed a systematic review of GWAS findings for antipsychotic efficacy or effectiveness. 14 studies met our inclusion criteria, ten of which examined antipsychotic response using quantitative rating scales to measure symptom improvement. 15 genome-wide significant loci were identified, seven of which were replicated in other antipsychotic GWAS publications: CNTNAP5, GRID2, GRM7, 8q24 (KCNK9), PCDH7, SLC1A1 and TNIK. Notably, four replicated loci are involved in glutamatergic pathways. Additional validation and evaluation of the biological significance of these markers is warranted. These markers should also be evaluated for clinical utility, especially in the con of other validated pharmacogenomic variants (e.g., CYP450 genes). These findings may generate new avenues for development of novel antipsychotic treatments.",
keywords = "GWAS, antipsychotic, genome-wide association study, pharmacogenomics, psychopharmacology, schizophrenia, systematic review, treatment response",
author = "Allen, {Josiah D.} and Bishop, {Jeffrey R}",
year = "2019",
month = "3",
doi = "10.2217/pgs-2018-0163",
language = "English (US)",
volume = "20",
pages = "291--306",
journal = "Pharmacogenomics",
issn = "1462-2416",
publisher = "Future Medicine Ltd.",
number = "4",

}

TY - JOUR

T1 - A systematic review of genome-wide association studies of antipsychotic response

AU - Allen, Josiah D.

AU - Bishop, Jeffrey R

PY - 2019/3

Y1 - 2019/3

N2 - Clinical symptom response to antipsychotic medications is highly variable. Genome-wide association studies (GWAS) provide a 'hypothesis-free' method of interrogating the genome for biomarkers of antipsychotic response. We performed a systematic review of GWAS findings for antipsychotic efficacy or effectiveness. 14 studies met our inclusion criteria, ten of which examined antipsychotic response using quantitative rating scales to measure symptom improvement. 15 genome-wide significant loci were identified, seven of which were replicated in other antipsychotic GWAS publications: CNTNAP5, GRID2, GRM7, 8q24 (KCNK9), PCDH7, SLC1A1 and TNIK. Notably, four replicated loci are involved in glutamatergic pathways. Additional validation and evaluation of the biological significance of these markers is warranted. These markers should also be evaluated for clinical utility, especially in the con of other validated pharmacogenomic variants (e.g., CYP450 genes). These findings may generate new avenues for development of novel antipsychotic treatments.

AB - Clinical symptom response to antipsychotic medications is highly variable. Genome-wide association studies (GWAS) provide a 'hypothesis-free' method of interrogating the genome for biomarkers of antipsychotic response. We performed a systematic review of GWAS findings for antipsychotic efficacy or effectiveness. 14 studies met our inclusion criteria, ten of which examined antipsychotic response using quantitative rating scales to measure symptom improvement. 15 genome-wide significant loci were identified, seven of which were replicated in other antipsychotic GWAS publications: CNTNAP5, GRID2, GRM7, 8q24 (KCNK9), PCDH7, SLC1A1 and TNIK. Notably, four replicated loci are involved in glutamatergic pathways. Additional validation and evaluation of the biological significance of these markers is warranted. These markers should also be evaluated for clinical utility, especially in the con of other validated pharmacogenomic variants (e.g., CYP450 genes). These findings may generate new avenues for development of novel antipsychotic treatments.

KW - GWAS

KW - antipsychotic

KW - genome-wide association study

KW - pharmacogenomics

KW - psychopharmacology

KW - schizophrenia

KW - systematic review

KW - treatment response

UR - http://www.scopus.com/inward/record.url?scp=85064139831&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064139831&partnerID=8YFLogxK

U2 - 10.2217/pgs-2018-0163

DO - 10.2217/pgs-2018-0163

M3 - Review article

C2 - 30883267

AN - SCOPUS:85064139831

VL - 20

SP - 291

EP - 306

JO - Pharmacogenomics

JF - Pharmacogenomics

SN - 1462-2416

IS - 4

ER -